simis
Encoxé à fond
paginate di imprecazioni e maledizioni contro il board!!!!!!!!!!!!!!!!!!!!!!!!
Veramente patetici!!!!!!!!!!!!!!!!
Company Profile
NICOXCodes and classification ISIN FR0000074130 Mnemo COX CFI ESVUFBMarket EURONEXT PARIS - Euronext - Local Securities Type Stock - Ordinary stock - Continuous Compartment B (Mid Caps)
ICB sectorial classificationIndustry: 4000, HealthCare
SuperSector: 4500, Health Care
Sector: 4570, Pharmaceuticals & Biotechnology
Subsector: 4577, Pharmaceuticals
Activity
NicOx specializes in the research and development of nitric oxide-donating compounds intended primarily for the treatment of inflammation and cardiometabolic diseases.
The company had a portfolio of five products under clinical development, including two in Phase II (notably NCX 116 for treating glaucoma), two in Phase I (notably antihypertensives-NO for treating hypertension), and one in Phase III (naproxcinod for treating the signs and symptoms of osteoarthritis).
NicOx has strategic partnership with some pharmaceutical and biotech companies among which Pfizer and Merck & Co.
Source: COFISEM - Last update: 04/11/10
Key figuresMillenium200920082007Revenue*1,1193,36220,620Operating profit*-61,985-79,213-37,198Net profit-60,350-73,887-32,144Shareholder's equity142,878102,069169,214Total assets157,425123,619189,461Fiscal year end12.0912.0812.07Length of fiscal year (months)121212Currency & UnitEUR - THOUSANDSEUR - THOUSANDSEUR - THOUSANDSAccount standardsIFRSIFRSIFRSSource: COFISEM - Last update: 04/11/10
AddressCalendars NicOx
Taissounières HB4 1681 route des Dolines BP 313
06906 Sophia Antipolis
France
Phone number:+33 (0)4 97 24 53 00
Fax:+33 (0)4 97 24 53 99
http://www.nicox.com
Company contactKarl HANKS
[email protected]
Phone number:+33 (0)4 97 24 53 42
Source: NICOX - Last update: 29/10/07 08:39 MET
Top managementChairman and Chief Executive OfficerMichele GarufiChief Financial OfficerEric CastaldiCommunicationsKarl HanksInvestor RelationsKarl HanksSource: COFISEM - Last update: 04/11/10
ShareholdersFond Stratégique d'Investissement5.48 %Oppenheimer Funds3.18 %Pfizer Overseas Pharmaceuticals1.87 %Blom Bank (Switzerland)1.4 %Bellevue Asset Management1.39 %Michele Garufi1.05 %Norges Bank Investment Management1.04 %Elisabeth Robinson0.72 %Credit Suisse Asset Management0.48 %Oddo Asset Management0.44 %Fortis Bank Nederland0.39 %Pictet & Cie0.37 %Axa Investment Managers Paris0.33 %Société Générale Bank and Trust0.31 %Crédit Agricole Asset Management0.3 %Crédit Agricole Suisse0.3 %HSBC Private Bank0.28 %Source: COFISEM - Last update: 04/11/10
ora spiegatemi perchè al 4 novembre nessuno di quresti soci ha liquidato posizioni :::::::::::::::::::
je ne crois pas que ce soit à jour ... on voit que Hanks figure toujours dans le board !